In murine glioma, HEV formation was induced by treatment with a vascular targeting peptide delivering LIGHT/TNFSF14 or when using a lymphotoxin β receptor agonist, and was further enhanced by anti-VEGF and ICI therapy (67, 68). The gene discussed is VEGFA; the disease is glioma.